ZURA vs. CMPX, ABOS, AGEN, IPHA, OPT, INMB, CHRS, IPSC, KOD, and FENC
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Agenus (AGEN), Innate Pharma (IPHA), Opthea (OPT), INmune Bio (INMB), Coherus BioSciences (CHRS), Century Therapeutics (IPSC), Kodiak Sciences (KOD), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.
Zura Bio (NASDAQ:ZURA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment.
Zura Bio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Compass Therapeutics received 13 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 72.73% of users gave Compass Therapeutics an outperform vote.
In the previous week, Compass Therapeutics had 22 more articles in the media than Zura Bio. MarketBeat recorded 22 mentions for Compass Therapeutics and 0 mentions for Zura Bio. Compass Therapeutics' average media sentiment score of 0.77 beat Zura Bio's score of 0.67 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Zura Bio presently has a consensus target price of $18.83, indicating a potential upside of 211.29%. Compass Therapeutics has a consensus target price of $9.00, indicating a potential upside of 462.50%. Given Compass Therapeutics' higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Zura Bio.
Compass Therapeutics' return on equity of -28.67% beat Zura Bio's return on equity.
61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 15.8% of Zura Bio shares are owned by insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Compass Therapeutics beats Zura Bio on 10 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
